Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow. Read why I rate KRYS ...
ascopubs.org

Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.

Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC ...
ascopubs.org

Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials

Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis Supported by National Key Research and Development ...

Quantum Breakthrough Turns Simple Forces Into Powerful New Interactions

Scientists have created a new way to generate powerful quantum interactions, achieving the first-ever demonstration of ...
Nature

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
NPR

Studio 2

April 24, 2026 Studio 2 Extra: Philly author Emma Copley Eisenberg A collection of short stories called “Fat Swim” by Philly author Emma Copley Eisenberg is slated for release on April 28th. In it, ...